Retatrutide (Reta)

Retatrutide represents a major advancement in peptide therapeutics for metabolic diseases. Developed by Eli Lilly, this synthetic peptide consists of 39 amino acids and is engineered with a C20 fatty diacid modification, which extends its half-life and enables convenient once-weekly subcutaneous dosing.

What sets retatrutide apart is its triple agonist mechanism: it simultaneously activates the GLP-1, GIP, and glucagon receptors—three critical regulators of energy balance and glucose metabolism.

This multi-receptor approach yields synergistic metabolic effects. GLP-1 receptor activation enhances insulin secretion, suppresses appetite, and slows gastric emptying. GIP receptor agonism further boosts insulin release and supports lipid metabolism. Meanwhile, glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation, with its hyperglycemic effects counterbalanced by the other two pathways.

Clinical data are compelling: In Phase 2 trials, retatrutide achieved up to 24.2% body weight reduction at 48 weeks with the highest dose, alongside HbA1c reductions of up to 2.02%—results that surpass those of dual agonists and many existing therapies.

Incretin-based drugs show a consistent safety profile, with gastrointestinal symptoms occurring most commonly as adverse events.

Beyond obesity and type 2 diabetes, retatrutide is under investigation for related conditions such as nonalcoholic steatohepatitis (NASH)

You may like to read: Tesamorelin 15mg